Prof. Dr. Michael Weller
Bevacizumab alone or in combination with irinotecan in recurrent WHO grade II and grade III gliomas
Seystahl K, Wiestler B, Hundsberger T, Happold C, Wick W, Weller M, Wick A. Bevacizumab alone or in combination with irinotecan in recurrent WHO grade II and grade III gliomas. Eur Neurol 2012; 69:95-101.
22.11.2012Bevacizumab alone or in combination with irinotecan in recurrent WHO grade II and grade III gliomas
22.11.2012Eur Neurol 2012; 69:95-101
Seystahl Katharina, Wiestler Benedikt, Hundsberger Thomas, Happold Caroline, Wick Wolfgang, Weller Michael, Wick Antje
Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials
Hofer S, Wick W, Zander T, Weder P, Roelcke U, Pichler J, Ochsenbein A, Marosi C, Lemke D, Huber U, Hottinger A, Greil R, Elandt K, Weller M. Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. Acta Oncol 2011; 50:630-5.
18.04.2011Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials
18.04.2011Acta Oncol 2011; 50:630-5
Hofer Silvia, Wick Wolfgang, Zander Thilo, Weder Patrik, Roelcke Ulrich, Pichler Josef, Ochsenbein Adrian, Marosi Christine, Lemke Dieter, Huber Urs, Hottinger Andreas F, Greil Richard, Elandt Katarzyna, Weller Michael
High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial
Thiel E, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Plasswilm L, Nägele T, Pietsch T, Bamberg M, Leithäuser M, Mergenthaler H, Hundsberger T, Korfel A, Martus P, Kanz L, Griesinger F, Rauch M, Röth A, Hertenstein B, von Toll T, Weller M. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol 2010; 11:1036-47.
20.10.2010High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial
20.10.2010Lancet Oncol 2010; 11:1036-47
Thiel Eckhard, Birnbaum Tobias, Fischer Lars, Jahnke Kristoph, Herrlinger Ulrich, Plasswilm Ludwig, Nägele Thomas, Pietsch Torsten, Bamberg Michael, Leithäuser Malte, Mergenthaler Hans-Günther, Hundsberger Thomas, Korfel Agnieszka, Martus Peter, Kanz Lothar, Griesinger Frank, Rauch Michael, Röth Alexander, Hertenstein Bernd, von Toll Theda, Weller Michael
Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03
Herrlinger U, Reifenberger G, Bamberg M, Sommer C, Tan T, Meyermann R, Wick W, Hundsberger T, Steinbach J, Kortmann R, Blaschke B, Loeser S, Koch D, Rieger J, Weller M. Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006; 24:4412-7.
20.09.2006Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03
20.09.2006Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006; 24:4412-7
Herrlinger Ulrich, Reifenberger Guido, Bamberg Michael, Sommer Clemens, Tan Ta-Chih, Meyermann Richard, Wick Wolfgang, Hundsberger Thomas, Steinbach Joachim P, Kortmann Rolf-Dieter, Blaschke Britta, Loeser Simon, Koch Dorothee, Rieger Johannes, Weller Michael